Abstract
Increasing evidence suggests that abnormalities in glutamatergic transmission may be associated with psychosis risk. Genetic polymorphisms associated with schizophrenia converge on NMDA receptor signalling pathways, and transgenic animal models and human neuroimaging studies have shown the functional impact of these risk alleles. Animal models have also shown that environmental risk factors, such as stress, cannabis use and maternal infection can result in glutamatergic dysfunction, and in vivo magnetic resonance spectroscopy (MRS) studies have detected glutamatergic abnormalities in individuals at clinical or genetic risk of psychosis. Glutamatergic dysfunction may impact on dopaminergic transmission, and ultimately lead to the emergence of psychosis. In this review, the evidence that genetic and environmental risk factors for psychosis impact on glutamatergic transmission is discussed. If glutamatergic abnormalities are present early in the disorder, this suggests that glutamatergic therapies may be useful in psychosis prevention.
Keywords: Glutamate, psychosis, risk, schizophrenia, magnetic resonance spectroscopy, prodromal period, at risk mental state, attenuated psychotic symptoms, dopamine neurons, hippocampus
Current Pharmaceutical Design
Title: Glutamate and Psychosis Risk
Volume: 18 Issue: 4
Author(s): Alice Egerton, Paolo Fusar-Poli and James M. Stone
Affiliation:
Keywords: Glutamate, psychosis, risk, schizophrenia, magnetic resonance spectroscopy, prodromal period, at risk mental state, attenuated psychotic symptoms, dopamine neurons, hippocampus
Abstract: Increasing evidence suggests that abnormalities in glutamatergic transmission may be associated with psychosis risk. Genetic polymorphisms associated with schizophrenia converge on NMDA receptor signalling pathways, and transgenic animal models and human neuroimaging studies have shown the functional impact of these risk alleles. Animal models have also shown that environmental risk factors, such as stress, cannabis use and maternal infection can result in glutamatergic dysfunction, and in vivo magnetic resonance spectroscopy (MRS) studies have detected glutamatergic abnormalities in individuals at clinical or genetic risk of psychosis. Glutamatergic dysfunction may impact on dopaminergic transmission, and ultimately lead to the emergence of psychosis. In this review, the evidence that genetic and environmental risk factors for psychosis impact on glutamatergic transmission is discussed. If glutamatergic abnormalities are present early in the disorder, this suggests that glutamatergic therapies may be useful in psychosis prevention.
Export Options
About this article
Cite this article as:
Egerton Alice, Fusar-Poli Paolo and M. Stone James, Glutamate and Psychosis Risk, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316244
DOI https://dx.doi.org/10.2174/138161212799316244 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell Sheet-Based Myocardial Tissue Engineering: New Hope for Damaged Heart Rescue
Current Pharmaceutical Design Biomarkers in Atrial Fibrillation and Heart Failure
Current Medicinal Chemistry Left Ventricular Hypertrophy Beyond Hemodynamics: Genetic, Metabolic and Hormonal Factors
Current Hypertension Reviews Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design Erythrocyte Cytoskeletal-plasma Membrane Protein Network in Rett Syndrome: Effects of ω-3 Polyunsaturated Fatty Acids
Current Proteomics A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews Role of Nanomedicines in Delivery of Anti-Acetylcholinesterase Compounds to the Brain in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Roles of p38-MAPK in Insulin Resistant Heart: Evidence from Bench to Future Bedside Application
Current Pharmaceutical Design The Growth Hormone Secretagogue Receptor (Ghs-R)
Current Pharmaceutical Design Anti-Amyloid Treatments in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem
Current Cardiology Reviews Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas
Anti-Cancer Agents in Medicinal Chemistry Efficient Expression and Purification of Recombinant Therapeutic Protein Candidates, Human Midkine and Pleiotrophin
Current Pharmaceutical Biotechnology Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Current Pharmaceutical Design Physiological Changes in the Critically Ill Patient with Sepsis
Current Pharmaceutical Biotechnology Tissue Engineering for Post-Myocardial Infarction Ventricular Remodeling
Mini-Reviews in Medicinal Chemistry Perioperative Considerations in Patients with Obstructive Sleep Apnea
Current Respiratory Medicine Reviews Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design Expression Profiles of Long Noncoding and Messenger RNAs in Epicardial Adipose Tissue-Derived from Patients with Coronary Atherosclerosis
Current Vascular Pharmacology